Caresyntax Announces New Chief Strategy Officer Rhonda Wallen

Rhonda Wallen is Boston-based Caresyntax GmbH’s new chief strategy officer and executive vice president of technology and evidence solutions. Caresyntax markets a digital surgery platform, utilizing both proprietary software and artificial intelligence to gather real-time operating room data and analysis for surgical teams and support staff.

Wallen, who brings over 25 years of industry experience to the role, will oversee medical devices and new business development. Most recently she served as senior vice president of Marketing and Development at Applied UV’s SteriLumen division. Wallen had also been head of corporate development for the blood and cellular technologies division of $5 billion global medical device company Terumo Corporation. She also served as chief operating officer of oncology therapeutics company Andarix and served as president and CEO of biotech company Caveo Therapeutics.

Caresyntax CEO and Co-Founder Dennis Kogan told OTW, “Rhonda brings deep leadership and expertise from her roles at both large multinational and emerging growth life science companies, as well as venture capital investing. Her diverse experience, including in biotech, diagnostics, and medtech, means she understands and will help to build solutions based on clinical and operational data and evidence as Caresyntax expands its partnerships with medical device companies to help meet the ever increasing demand for data-driven, real-world insights into surgery.”

Kogan continued, “Rhonda’s background provides a fantastic foundation for working with our medical device partners to leverage the power of our platform to help demonstrate the value of medtech products in a complex reimbursement and purchasing environment. As we increase our engagement with the medical device industry and with orthopedics companies in particular, Rhonda will be a great partner to the medtech C-Suite in developing a digital ecosystem around their products, ultimately enabling them to increase connection with their customers and improve patient outcomes using real-world data insights.”

Caresyntax also solidified its increased ambitions to serve medical technology companies by additionally announcing it has joined trade association AdvaMed, the Advanced Medical Technology Association. AdvaMed is currently the largest med tech trade organization globally.

AdvaMed advocates for patient access to life-saving medical tech of the highest safety standards. AdvaMed’s Center for Digital Health promotes public policy to advance digital health and the use of data-driven health healthcare via advanced medical technology. Wallen will also lead Caresyntax’s work with AdvaMed.

The announcements coincide with a marked growth area for Caresyntax. The company recently secured $100 million in Series C, led by healthcare investment firm PFM Health Sciences LP.

“Caresyntax has proven to be a trusted partner for over 1,000 hospitals, and I look forward to building on this solid foundation to bring the value of the Caresyntax platform to medical device companies,” stated Wallen. “Medtech companies face increasing pressure to demonstrate their impact on lowering cost of care and improving patient outcomes. It is exciting to enable these companies’ continuous improvement with digital innovations, guided by real-world data.”